The high efficiency, human B cell immortalizing heteromyeloma CB-F7

Grunow, Roland; Jahn, S.; Porstmann, T; Kiessig, S S; Steinkellner, Herta; Steindl, Franz; Mattanovich, Diethard; Gürtler, Leo; Deinhardt, F; Katinger, Hermann

doi:10.1016/0022-1759(88)90206-2

Cited by 100 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each stable line described above produces IgG. Most human mAbs to HIV described by other groups are also IgGs (19)(20)(21)(22). Yet most human mAbs produced by EBV transformation are IgM (29).…”

Section: Resultsmentioning

confidence: 99%

Generation of human monoclonal antibodies to human immunodeficiency virus.

Górny

Gianakakos

Sharpe

et al. 1989

Proc. Natl. Acad. Sci. U.S.A.

170

129

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Generation of human monoclonal antibodies to human immunodeficiency virus.

Górny

Gianakakos

Sharpe

et al. 1989

Proc. Natl. Acad. Sci. U.S.A.

170

129

View full text Add to dashboard Cite

show abstract

“…Human mAb 50-69 directed against the HIV transmembrane protein gp4l and mAb 71-31 directed to the core protein p24, described by Gorny et al (22), were tested in parallel and displayed essentially no neutralizing activity for either strains of HIV. DISCUSSION Despite the technical difficulties encountered over the past decade in producing human mAbs, several have been obtained to HIV (11,22,(33)(34)(35)(36)(37)(38)(39)(40). The success in generating human mAbs to HIV, as opposed to other antigens, appears to be due to the chronic antigenic stimulation of HIV-infected individuals that results in hyperimmunization and continual circulation of Ab-producing B cells.…”

Section: Resultsmentioning

confidence: 99%

“…herein was designed to pick cells producing Abs to a particular neutralizing domain rather than identifying mAbs to random HIV epitopes as was previously done (11,22,(33)(34)(35)(36)(37)(38)(39)(40).…”

Section: Resultsmentioning

confidence: 99%

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Górny

Gianakakos

et al. 1991

Proc. Natl. Acad. Sci. U.S.A.

166

135

View full text Add to dashboard Cite

Cell lines secreting IgG1 human monoclonal antibodies (mAbs) to the envelope glycoprotein, gpl2O, of human immunodeficiency virus (IRV) have been produced by transformation of peripheral blood cells front IIV-infected individuals and by fusion of transformed cells to a humanmouse heteromyeloma cell line (SHM-D33). Two human mAbs were site-selected by means of a 23-mer synthetic peptide spanning a portion of the third variable domain of gpI20 from the MN strain of HIV. The two heterohybridomas produce three times more IgG than do their parent lymphoblastoid cell lines. The specificities of these mAbs have been mapped to sequences near the tip of the disulfide loop of the gpl20 third variable domain, Lys-Arg-lle-His-Ile and His-Ie-Gly-Pro-GlyArg, respectively. The mAbs have dissociation constants of 3.7 x 10-6 M and 8.3 x 10-7 M, neutralize HIVMN in vitro at nanogram levels, and bear the characteristics of antibodies associated with protective immunity in vivo.

show abstract

“…Charilc Hospital, Berlin, Germany), a HAT-sensilive, ouabainresistant non-secreting cell line by PEG 1500 (Boehringer Mannheim, Germany). The fusion protocol was performed according to Grunow et al [14]. Cells were seeded in flalbottomed microtitre plates (Nunc) with 10' cells/well, 100 fiXj well.…”

Section: Fusion With Cb-f7mentioning

confidence: 99%

Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients

Ehrenstein¹,

Longhurst²,

Isenberg³

1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThis study compares recently devised tnethods for producing IgG anti-DNA MoAbs from patients with SLE and analyses the antibodies generated from one patient at different phases of disease. Lymphocytes from SLE patients were transformed with Epstein-Barr virus (EBV) and/or fused with a heteromyeloma cell line., CB-F7. Direct fusion with CB-F7 resulted in the highest proportion of lgG-secreting lines, whereas EBV transformation resulted in a high percentage of IgM-secreting lines. Using direet fusion, five IgM anti-DNA antibody-seereting hybridomas were generated using lymphoeytes from a patient with relatively inactive SLE. Six months later when the disease was active, only IgG anti-DNA antibodies were produced. The antigen-binding patterns of the MoAbs were analysed. Only one of the IgM anti-DNA antibodies reacted with dsDNA by ELISA and none by Crithidia immunofluorescenee, whereas two ofthe IgG antibodies reacted with dsDNA by ELISA and Crithidia but did not bind to ssDNA. Only the two IgG high affinity anti-dsDNA antibodies bound to histones, and this was enhanced by added DNA. whereas three IgM antibodies bound lo cardiolipin. This study supports the notion that MoAbs derived from a patient with SLE represent those found in the serum of SLE patients at different stages of disease aetivity. The binding to histones by the two IgG anti-dsDNA antibodies supports the recently expressed view that antibodies binding DNA/histone may be important in the pathogenesis of SLE.

show abstract

The high efficiency, human B cell immortalizing heteromyeloma CB-F7

Cited by 100 publications

References 18 publications

Generation of human monoclonal antibodies to human immunodeficiency virus.

Generation of human monoclonal antibodies to human immunodeficiency virus.

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients

Contact Info

Product

Resources

About